Evidence map›Paper›PMID 22730931›Full record

SynthesisBMC musculoskeletal disorders2012

The reporting quality of studies investigating the diagnostic accuracy of anti-CCP antibody in rheumatoid arthritis and its impact on diagnostic estimates.

Elias Zintzaras, Afroditi A Papathanasiou, Dimitrios C Ziogas, Michael Voulgarelis

Abstract readMeta-AnalysisReview
In one paragraph

Synthesis in BMC musculoskeletal disorders, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Anti-CCP: a truly helpful rheumatoid arthritis test?Canadian family physician Medecin de famille canadien · 2016
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Elias ZintzarasDepartment of Biomathematics, University of Thessaly School of Medicine, 2 Panepistimiou Str, Larissa, 41110, Greece. zintza@med.uth.gr
Afroditi A Papathanasiou
Dimitrios C Ziogas
Michael Voulgarelis

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecently anti-CCP testing has become popular in the diagnosis of rheumatoid arthritis (RA). However, the inadequate reporting of the relevant diagnostic studies may overestimate and bias the results, directing scientists into making false decisions. The aim of the present study was to evaluate the reporting quality of studies used anti-CCP2 for the diagnosis of RA and to explore the impact of reporting quality on pooled estimates of diagnostic measures.

methodsPubMed was searched for clinical studies investigated the diagnostic accuracy of anti-CCP. The studies were evaluated for their reporting quality according to STARD statement. The overall reporting quality and the differences between high and low quality studies were explored. The effect of reporting quality on pooled estimates of diagnostic accuracy was also examined.

resultsThe overall reporting quality was relatively good but there are some essential methodological aspects of the studies that are seldom reported making the assessment of study validity difficult. Comparing the quality of reporting in high versus low quality articles, significant differences were seen in a relatively large number of methodological items. Overall, the STARD score (high/low) has no effect on the pooled sensitivities and specificities. However, the reporting of specific STARD items (e.g. reporting sufficiently the methods used in calculating the measures of diagnostic accuracy and reporting of demographic and clinical characteristics/features of the study population) has an effect on sensitivity and specificity.

conclusionsThe reporting quality of the diagnostic studies needs further improvement since the study quality may bias the estimates of diagnostic accuracy.

Indexed as

Immunologic TestsArthritis, RheumatoidAutoantibodiesHumansPeptides, CyclicPredictive Value of TestsPrognosisReproducibility of ResultsResearch DesignSensitivity and SpecificitySeverity of Illness IndexAutoantibodiescyclic citrullinated peptidePeptides, Cyclic

Identifiers

PMID22730931
PMCPMC3488511

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.